Kezar Life Sciences, Inc. (KZR)

0.7900 +0.0024 (+0.30%) At close: 04:00PM EDT

Kezar Life Sciences, Inc.

4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 822 5600
https://www.kezarlifesciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christopher J. Kirk Ph.D.	Co-Founder, CEO & Director	677.41k	N/A	1973
Mr. John Franklin Fowler	Co-Founder & Director	919.91k	N/A	1972
Dr. Jack Taunton Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Marc L. Belsky	CFO & Secretary	491.79k	N/A	1955
Ms. Gitanjali Jain	Vice President of Investor Relations & External Affairs	N/A	N/A	N/A
Mr. Mark Schiller	Chief Legal Officer	N/A	N/A	N/A
Dr. Neel K. Anand Ph.D.	Senior Vice President of Research & Drug Discovery	N/A	N/A	N/A
Dr. Nick Mordwinkin Ph.D., Pharm.D.	Chief Business Officer & Head of Strategy	N/A	N/A	1981
Mr. Zung To	Senior Vice President of Clinical Development	N/A	N/A	N/A
Ms. Pattie Chiang	VP & Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate governance

Kezar Life Sciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.